0093 ± 0.0010, respectively, and were significant different (t = 2.845, P = 0.006). L1CAM was over-buy NVP-HSP990 expressed in 25 gastric tumor tissue samples compared with matched normal gastric mucosa. In 42 gastric tumor tissue samples and matched normal gastric mucosa, the average expressions of EPCAM were 0.4199 ± 0.0485 AZD9291 in vivo and 0.1759 ± 0.0144, respectively, and were significantly different (t = 3.122, P = 0.002). EPCAM was over-expressed in 27 gastric tumor tissue samples compared with matched normal gastric mucosa. Figure 1 Expression of L1CAM mRNA in gastric cancer cell lines. Figure 2 Expression of EPCAM mRNA in gastric cancer cell lines. Expression of L1CAM and EPCAM in archived gastric

cancer tissue and non-cancer mucosa L1CAM protein was detected in 22/92 (23.9%) human non-tumor mucosa samples; all samples expressed L1CAM protein

at low levels. High L1CAM protein expression was detected in 163 (27.1%) tumors. L1CAM was localized mainly in the cytoplasm of primary cancer cells (Figure 3). Figure 3 Immunohistochemical staining for L1CAM in gastric cancer lesions (601 case) and noncancerous tissues (92 case). A: L1CAM was negative in noncancerous tissues, B: L1CAM was highly expressed in well differentiated adenocarcinoma, C: L1CAM was highly expressed in moderately differentiated adenocarcinoma, Metabolism inhibitor D: L1CAM was highly expressed in poorly differentiated adenocarcinoma. EPCAM protein was detected in 42/92 (45.7%) human non-tumor mucosa samples; all samples expressed Clomifene EPCAM protein

at a low level. High EPCAM protein expression was detected in 247 (41.1%) tumors, EPCAM was localized mainly in the cytoplasm of primary cancer cells (Figure 4). Figure 4 Immunohistochemical staining for EPCAM in gastric cancer lesions (601 case) and noncancerous tissues (92 case). A: EPCAM was negative in noncancerous tissues, B: EPCAM was highly expressed in well differentiated adenocarcinoma, C: EPCAM was highly expressed in moderately differentiated adenocarcinoma, D: EPCAM was highly expressed in poorly differentiated adenocarcinoma. L1CAM and EPCAM overexpression and clinicopathological features Expression of L1CAM correlated with age, tumor location, tumor size, Lauren’s classification, depth of invasion, lymph node and distant metastases, regional lymph node stage and TNM stage (P < 0.05). L1CAM expression did not correlate with sex, differentiation, or histological classification (P>0.05; Table 1). Table 1 Relationship of L1CAM expression with pathological parameters of tumor Clinical parameters L1CAM   Low High t/χ2/r P Age(yrs) 57.86 ± 11.88 61.20 ± 11.85 3.065 0.002 Gender     3.386 0.066 Male 321 (75.0%) 107 (25.0%)     Female 117 (67.6%) 56 (32.4%)     Location     13.39 0.001 Proximal 54 (64.3%) 30 (35.7%)     Middle 150 (67.3%) 73 (32.7%)     Distal 234 (79.6%) 60 (20.4%)     Size     26.99 0.0001 <5 cm 283 (80.9%) 67 (19.1%)     ≥5 cm 155 (61.8%) 96 (38.2%)     Lauren classification     94.92 0.0001 Intestinal 271 (90.6%) 28 (9.4%)     Diffuse 167 (55.